

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE BY SECURED PARTY

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Prolog Capital II, L.P.		04/29/2010	LIMITED PARTNERSHIP: MISSOURI
Charter Life Sciences, L.P.		04/29/2010	LIMITED PARTNERSHIP: DELAWARE
Memphis Biomed Ventures II, L.P.		04/30/2010	LIMITED PARTNERSHIP: DELAWARE
Triathlon Medical Ventures Fund, L.P.		05/02/2010	LIMITED PARTNERSHIP: DELAWARE
Advantage Capital Community Development Fund XV, LLC		05/02/2010	LIMITED LIABILITY COMPANY: LOUISIANA
Alafi Capital Company, LLC		05/02/2010	LIMITED LIABILITY COMPANY: CALIFORNIA
Apjohn Ventures Fund, LP		05/02/2010	LIMITED PARTNERSHIP: DELAWARE
Vectis Life Sciences Fund I, L.P.		05/02/2010	LIMITED PARTNERSHIP: DELAWARE
Samuel A. Wickline M.D.		05/02/2010	INDIVIDUAL:
1998 Co-Investing LLC		05/02/2010	LIMITED LIABILITY COMPANY: MISSOURI
C. Aganostopoulos Revocable Trust U/A 12/21/1978		05/02/2010	TRUST: MICHIGAN

**RECEIVING PARTY DATA**

<b>Name:</b>	Kereos, Inc.
<b>Street Address:</b>	4041 Forest Park Ave.
<b>City:</b>	St. Louis
<b>State/Country:</b>	MISSOURI
<b>Postal Code:</b>	63108
<b>Entity Type:</b>	CORPORATION:

PROPERTY NUMBERS Total: 1

**900161140**

**TRADEMARK  
 REEL: 004197 FRAME: 0502**

**CH \$40.00 2896270**

Property Type	Number	Word Mark
Registration Number:	2896270	KEREOS

**CORRESPONDENCE DATA**

Fax Number: (314)667-3633  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 314-552-6000  
Email: ipdocket@thompsoncoburn.com  
Correspondent Name: Tiffany L. Schwartz  
Address Line 1: One US Bank Plaza  
Address Line 4: St. Louis, MISSOURI 63101

ATTORNEY DOCKET NUMBER:	44211-54099
NAME OF SUBMITTER:	Tiffany L. Schwartz
Signature:	/Tiffany L. Schwartz/
Date:	05/03/2010

**Total Attachments: 11**  
source=Release of Security Interest#page1.tif  
source=Release of Security Interest#page2.tif  
source=Release of Security Interest#page3.tif  
source=Release of Security Interest#page4.tif  
source=Release of Security Interest#page5.tif  
source=Release of Security Interest#page6.tif  
source=Release of Security Interest#page7.tif  
source=Release of Security Interest#page8.tif  
source=Release of Security Interest#page9.tif  
source=Release of Security Interest#page10.tif  
source=Release of Security Interest#page11.tif

## RELEASE OF SECURITY INTEREST

THIS RELEASE OF SECURITY INTEREST (this "Release") is made and entered into as of the 23rd day of April, 2010, by: Prolog Capital II, L.P., a Missouri limited partnership; Charter Life Sciences, L.P., a Delaware limited partnership; Memphis Biomed Ventures II, L.P., a Delaware limited partnership; Triathlon Medical Ventures Fund, L.P., a Delaware limited partnership; Advantage Capital Community Development Fund XV, LLC, a Louisiana limited liability company; Alafi Capital Company, LLC, a California limited liability company; Apjohn Ventures Fund, L.P., a Delaware limited partnership; Vectis Life Sciences Fund I, L.P., a Delaware limited partnership; Samuel A. Wickline, M.D., an individual; 1998 Co-Investing, LLC, a Missouri limited liability company; and C. Aganostopolous Revocable Trust U/A 12/21/1978, a trust organized under the laws of the State of Michigan (collectively, "Secured Party"), in favor of Kereos, Inc., a Delaware corporation having offices at 4041 Forest Park Ave., St. Louis, Missouri 63108 ("Kereos").

Secured Party hereby releases its liens and security interests and resigns any and all right, title, and interest it may have in and to those patents and patent applications listed in **Schedules A and B** under the document executed June 15, 2009 and recorded with the United States Patent and Trademark Office on July 17, 2009 at reel and frame numbers 022960/0670 and in and to the trademarks and trademark registrations and applications listed in **Schedules C and D** attached hereto, under the document executed June 15, 2009 and recorded with the United States Patent and Trademark Office on July 17, 2009, at reel and frame numbers 004026/0614.

IN WITNESS WHEREOF, the undersigned has caused this Release of Security Interest to be executed by its duly authorized officer as of the signature date below. In accordance with the Patent, Trademark, and License Security Agreement being released herein, signature by a majority-in-interest of the above-named parties shall constitute the action, consent and approval of this Release by the Secured Party.

*Signature pages follow.*

[Signature page – Prolog Capital II, L.P.]

**PROLOG CAPITAL II, L.P.**

**By: Prolog Ventures II, LLC, its General Partner**

By:  OR MAN

Name: GREGORY R. JOHNSON

Title: MANAGING DIRECTOR


4/29/10  
Date

[Signature page – Charter Life Sciences, L.P.]

**CHARTER LIFE SCIENCES, L.P.**

**By: CLS Management, LLC, General Partner of  
CLS Partners, L.P., General Partner of Charter  
Life Sciences, L.P.**

By:



Name:

Fred M Schwanzer

Title:

Managing Partner


Date

4/29/2010

[Signature page – Memphis Biomed Ventures II, L.P.]

**MEMPHIS BIOMED VENTURES II, L.P.**

**By: MB Venture Partners, its General Partner**

By: 

Name: STEPHEN SNOWDY

Title: PARTNER

30 April 2010  
Date

**TRIATHLON MEDICAL VENTURES FUND, L.P.**

**By: Triathlon Medical Ventures, LLC, its General Partner**

By: 

Name: JOHN M. RICE

Title: MANAGING PARTNER

5/2/10  
Date

**SCHEDULE A**

**United States Patents**

<b>TITLE</b>	<b>APPLICATION # FILING DATE</b>	<b>PATENT # GRANT DATE</b>
LIPOPHILIC DERIVATIVES OF CHELATE MONOAMIDES	11/146,651 6/7/2005	7,504,088 03/17/2009 Expiry: 06/07/2025
AVIDIN-BOITIN CONJUGATED EMULSIONS AS A SITE SPECIFIC BINDING SYSTEM	08/488,743 6/8/1995	5,690,907 11/25/1997 Expiry: 06/08/2015
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	09/026,216 2/19/1998	5,989,520 11/23/1999 Expiry: 05/23/2016
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	10/036,317 12/28/2001	6,821,506 11/23/2004 Expiry: 09/24/2019
METHODS FOR TARGETED DRUG DELIVERY	10/302,369 11/22/2002	7,186,399
METHOD OF MRI USING AVIDIN-BIOTIN CONJUGATED EMULSIONS AS A SITE SPECIFIC BINDING SYSTEM	08/647,277 5/23/1996	5,780,010 07/14/1998 Expiry: 06/08/2015
SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS	08/989,979 12/12/1997	5,958,371 09/28/1999 Expiry: 05/23/2016
SITE SPECIFIC BINDING SYSTEM, NUCLEAR IMAGING COMPOSITIONS AND METHODS	09/404,963 9/24/1999	6,548,046 04/15/2003 Expiry: 11/09/2018
LIGAND-TARGETED EMULSIONS CARRYING BIOACTIVE AGENTS	09/697,796 10/27/2000	6,676,963 01/13/2004 Expiry: 10/27/2020
ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE-CONTRAST AGENTS	09/774,278 1/30/2001	7,179,449 02/20/2007 Expiry: 01/30/2021
INTERGRIN TARGETED IMAGING AGENTS	10/351,463 1/24/2003	7,255,875 08/14/2007 Expiry: 01/24/2023
INTEGRIN TARGETED IMAGING AGENTS	11/305,416 12/16/2005	7,344,698 03/18/2008 Expiry: 01/24/2023
PARAMAGNETIC PARTICLES THAT PROVIDE IMPROVED RELAXIVITY	10/153,395 5/21/2002	6,869,591 03/22/2005 Expiry: 05/21/2022



TITLE	APPLICATION # FILING DATE	PATENT # GRANT DATE
PARAMAGNETIC PARTICLES THAT PROVIDE IMPROVED RELAXIVITY	10/400,379 3/26/2003	7,235,227 06/26/2007 Expiry: 05/21/2022
BLOOD CLOT-TARGETED NANOPARTICLES	10/225,024 8/20/2002	7,220,401
CHELATING AGENTS WITH LIPOPHILIC CARRIERS	10/765,299 1/26/2004	7,279,150 10/09/2007 Expiry: 01/26/2024

**SCHEDULE B****United States Patent Applications**

<b>TITLE</b>	<b>APPLICATION # FILING DATE</b>
NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES	12/043,063 3/5/2008
COMBINATION ANTITUMOR THERAPIES	12/160,091 1/3/2007
IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS	11/872,984 10/16/2007
ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE-DEPENDENT CONTRAST AGENTS	11/677,040 2/20/2007
INTEGRIN TARGETED IMAGING AGENTS	11/971,818 1/9/2008
BLOOD CLOT-TARGETED NANOPARTICLES	10/544,857 8/20/2003
BLOOD CLOT-TARGETED NANOPARTICLES	11/796,064 4/25/2007
CHELATING AGENTS WITH LIPOPHILIC CARRIERS	11/869,685 10/9/2007
EMULSION PARTICLES FOR IMAGING AND THERAPY AND METHODS OF USE THEREOF	10/913,846 8/6/2004
ENHANCED DRUG DELIVERY	10/993,578 11/19/2004
IMPROVED EFFICACY AND SAFETY OF TARGETED PARTICULATE AGENTS WITH DECOY SYSTEMS	10/588,572 2/10/2005
TARGETED ATHEROSCLEROSIS TREATMENT	10/492,749 1/16/2004

TITLE	APPLICATION # FILING DATE
METHODS TO AMELIORATE AND IMAGE ANGIOPLASTY-INDUCED VASCULAR INJURY	11/607,683 12/1/2006
METHODS OF IMAGING EMPLOYING CHELATING AGENTS	11/944,271 11/21/2007
TARGETED MR IMAGING AGENTS	11/693,647 3/29/2007
DETECTION AND IMAGING OF TARGET TISSUE	11/796,415 4/27/2007
COMBINATIONS FOR TREATMENT OF NEOVASCULATURE	11/865,603 10/1/2007

**SCHEDULE C**

**United States Trademarks**

<u>Trademark No.</u>	<u>Date Issued</u>	<u>Description</u>
2,896,270	October 19, 2004	"KEREOS"

**SCHEDULE D**

**United States Trademark Applications**

Application No.

Date Filed

Mark

None